Chronic Kidney Disease in Children

Overview

Progression of chronic kidney disease (CKD) in children leads to end stage renal disease (ESRD), which is associated with mortality rates 30-150 times higher than the general pediatric population. The traditional biomarkers, serum creatinine and proteinuria, are used to predict progression of CKD in clinical trials even though both correlate poorly with the progression of CKD and the response to interventions. There are numerous candidate therapies for CKD, but with a continued reliance on serum creatinine and proteinuria, clinical trials will likely continue to fail. 

The field of CKD biomarkers in children is a very promising area of research with a small amount of resources invested to date. Predicting progression of CKD will allow clinicians to better time follow-up, referral for transplant, and provide better guidance to families. More importantly, an optimal panel of biomarkers and risk prediction model can replace proteinuria and serum creatinine in biomarker guided clinical trials. We plan to measure urine and serum biomarkers of kidney injury, inflammation, repair, and fibrosis from the samples of the children enrolled in the CKD in Children (CKiD) cohort and Assessment, Serial Evaluation, and Subsequent Sequelae in AKI (ASSESS-AKI) cohort. Our ultimate goal is to facilitate clinical trials for children with CKD in order to identify new treatments.

Bio Profile

Chirag R Parikh, MD, PhD, FACP

Professor of Medicine (Nephrology)

Director, Program of Applied Translational Research

View Full Profile

Susan L. Furth, MD, PhD

The University of Pennsylvannia

CKD in Children

Contact Information

For more information, or if you are interested in collaborating on this study, please contact Jason Greenberg

Project Funding

Funding for this project comes, in part, from the following grants:

K08 DK110536 (NIH-NIDDK)

"Novel Biomarkers of Chronic Kidney Disease Progression in Children"